Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.83 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.83 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.41 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386838 | 1.00 | KDM1A (0.83) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| SCHEMBL19386821 | 0.94 | KDM1A (0.80) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| SCHEMBL17882111 | 0.94 | KDM1A (0.80) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| SCHEMBL19386977 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| SCHEMBL19386984 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| Polymyxin B5 SCHEMBL21258460 | 0.93 | KDM1A (0.91) | KDM1ARCOR1PSMB5PSMB2 | |
| Polymyxin B3 SCHEMBL21474115 | 0.93 | KDM1A (0.91) | KDM1ARCOR1PSMB5PSMB2 | |
| Polymyxin B4 SCHEMBL21476967 | 0.93 | KDM1A (0.91) | KDM1ARCOR1PSMB5PSMB2 | |
| SCHEMBL19386868 | 0.92 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2TERF2IP | |
| SCHEMBL19386975 | 0.92 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2TERF2IP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | KDM1A 4119/4885RCOR1 4858/4885PSMB5 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.